



2558P-13-4.ST25.txt  
SEQUENCE LISTING

<110> Blake, James  
Cole, Carol-Ann  
Coleman, Patrick F.  
Monji, Nobuo  
Montana, John P.

<120> CYSTEINE THIOL-PROTECTED PEPTIDES FOR USE IN IMMUNOASSAYS

<130> 025580-001340US

<140> 09/733,239

<141> 2000-12-08

<150> US 08/462,749

<151> 1995-06-05

<150> US 08/140,696

<151> 1993-10-21

<150> US 07/532,429

<151> 1990-06-04

<150> US 07/360,513

<151> 1989-06-02

<160> 16

<170> PatentIn version 3.1

<210> 1

<211> 26

<212> PRT

&lt;213&gt; HIV-1

&lt;400&gt; 1

Arg Ile Leu Ala Val Glu Arg Tyr Leu Lys Asp Gln Gln Leu Leu Gly  
 1 5 10 15

Ile Trp Gly Cys Ser Gly Lys Leu Ile Cys  
 20 25

&lt;210&gt; 2

&lt;211&gt; 26

&lt;212&gt; PRT

&lt;213&gt; HIV-2

&lt;400&gt; 2

Arg Val Thr Ala Ile Glu Lys Tyr Leu Gln Asp Gln Ala Arg Leu Asn  
 1 5 10 15

Ser Trp Gly Cys Ala Phe Arg Gln Val Cys  
 20 25

&lt;210&gt; 3

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; HIV-2

&lt;400&gt; 3

Gln Asp Gln Ala Arg Leu Asn Ser Trp Gly Cys Ala Phe Arg Gln Val  
 1 5 10 15

Cys

&lt;210&gt; 4

&lt;211&gt; 23

&lt;212&gt; PRT

&lt;213&gt; HTLV-1

&lt;400&gt; 4

Gln Asn Arg Arg Gly Leu Asp Leu Leu Phe Trp Glu Gln Gly Gly Cys  
 1 5 10 15

Lys Ala Leu Gln Glu Gln Cys  
20

<210> 5

<211> 24

<212> PRT

<213> HTLV-2

<400> 5

Gln Asn Arg Arg Gly Leu Asp Leu Leu Phe Trp Glu Gln Gly Gly Leu  
1 5 10 15

Cys Lys Ala Ile Gln Glu Gln Cys  
20

<210> 6

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide 39 (SEQ 1) with Cys Gly Gly peptide arm

<400> 6

Cys Gly Gly Arg Ile Leu Ala Val Glu Arg Tyr Leu Lys Asp Gln Gln  
1 5 10 15

Leu Leu Gly Ile Trp Gly Cys Ser Gly Lys Leu Ile Cys  
20 25

<210> 7

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide 41-2-1 (SEQ 2) with Cys Gly Gly peptide arm

<400> 7

Cys Gly Gly Arg Val Thr Ala Ile Glu Lys Tyr Leu Gln Asp Gln Ala  
1 5 10 15

2558P-13-4.ST25.txt

Arg Leu Asn Ser Trp Gly Leu Ala Phe Arg Gln Val Cys  
20 25

<210> 8

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide 41-2-3 (SEQ 3) with Cys Gly Gly peptide arm

<400> 8

Cys Gly Gly Gln Pro Gln Ala Arg Leu Asn Ser Trp Gly Cys Ala Phe  
1 5 10 15

Arg Gln Val Cys  
20

<210> 9

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide 121-1 (SEQ 4) with Cys Gly Gly peptide arm

<400> 9

Cys Gly Gly Gln Asn Arg Arg Gly Leu Asp Leu Leu Phe Trp Glu Gln  
1 5 10 15

Gly Gly Leu Cys Lys Ala Leu Gln Glu Gln Cys  
20 25

<210> 10

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide 221-1 (SEQ 5) with Cys Gly Gly peptide arm

&lt;400&gt; 10

Cys Gly Gly Gln Asn Arg Arg Gly Leu Asp Leu Leu Phe Trp Glu Gln  
 1 5 10 15

Gly Gly Leu Cys Lys Ala Ile Gln Glu Gln Cys  
 20 25

&lt;210&gt; 11

&lt;211&gt; 28

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Peptide 39 with Thr and C-terminal thioglycine residue

&lt;400&gt; 11

Arg Ile Leu Ala Val Glu Arg Tyr Leu Lys Asp Gln Gln Leu Leu Gly  
 1 5 10 15

Ile Trp Gly Cys Ser Gly Lys Leu Ile Cys Thr Gly  
 20 25

&lt;210&gt; 12

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Pentadysine

&lt;400&gt; 12

Lys Lys Lys Lys Lys  
 1 5

&lt;210&gt; 13

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; HTLV-1

&lt;400&gt; 13

Gly Leu Asp Leu Leu Phe Trp Glu Gln Gly Gly Leu Cys Lys Ala Leu  
 1 5 10 15

Gln Glu Gln Cys  
20

<210> 14

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide 121-2 (SEQ 13) with Cys Gly Gly peptide arm

<400> 14

Cys Gly Gly Gly Leu Asp Leu Leu Phe Trp Glu Gln Gly Gly Leu Cys  
1 5 10 15

Lys Ala Leu Gln Glu Gln Cys  
20

<210> 15

<211> 16

<212> PRT

<213> HTLV-2

<400> 15

Asn Arg Arg Gly Leu Asp Leu Leu Phe Trp Glu Gln Gly Gly Leu Cys  
1 5 10 15

<210> 16

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide 121-3 (SEQ 15) with Cys Gly Gly peptide arm

<400> 16

Cys Gly Gly Asn Arg Arg Gly Leu Asp Leu Leu Phe Trp Glu Gln Gly  
1 5 10 15

Gly Leu Cys

2558P-13-4.ST25.txt